The Oncology Institute (TOI) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
30 Apr, 2026Executive summary
Annual meeting scheduled for June 17, 2026, to be held virtually for stockholders of record as of April 24, 2026.
Proxy materials, including the Notice of Meeting, Proxy Statement, and Annual Report on Form 10-K, are available online, with paper copies available upon request.
Voting matters and shareholder proposals
Election of eight directors is up for vote.
Ratification of BDO as the independent registered public accounting firm for 2026.
Advisory vote on executive compensation (say-on-pay) is included.
Advisory vote on the preferred frequency of future say-on-pay votes is proposed, with the board recommending a 1-year frequency.
Board of directors and corporate governance
Eight nominees for director positions are listed: Brad Hively, Karen Johnson, Mohit Kaushal, Anne McGeorge, Mark Pacala, Mark Stolper, Kimberly Tzoumakas, and Daniel Virnich.
Latest events from The Oncology Institute
- Board recommends voting for all proposals, emphasizing governance and executive pay alignment.TOI
Proxy filing30 Apr 2026 - Delegated contracts and dispensary growth drive profitability and expansion through 2028.TOI
25th Annual Needham Virtual Healthcare Conference15 Apr 2026 - Achieved 28% revenue growth and breakeven Adjusted EBITDA in 2025, with profitability expected in 2026.TOI
Investor presentation16 Mar 2026 - First profitable quarter on adjusted EBITDA, with strong revenue growth and improved 2026 outlook.TOI
Q4 202512 Mar 2026 - Record value-based contract growth and operational focus drive margin and cash flow improvements.TOI
Jefferies 2024 Global Healthcare Conference1 Feb 2026 - Q2 revenue up 23% to $98.6M, but margin pressures and contract changes prompt strategic review.TOI
Q2 20241 Feb 2026 - Q3 2024 revenue up 21.8% with strong Dispensary growth and improved net loss.TOI
Q3 202414 Jan 2026 - 2024 revenue rose 21.3% with improved cash flow; 2025 targets profitability and growth.TOI
Q4 202426 Dec 2025 - 27.9M shares registered for resale; proceeds from warrants to fund growth in value-based oncology.TOI
Registration Filing16 Dec 2025